Literature DB >> 9267740

Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis.

R Feldmann1, H Löw-Weiser, P Duschet, F Gschnait.   

Abstract

We report a patient with multiple sclerosis who was receiving subcutaneous injections of recombinant interferon beta. During the third month of treatment, painful necrotizing cutaneous lesions appeared at the injection sites. The possible pathogenesis of interferon-induced skin necrosis is discussed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9267740     DOI： 10.1159/000245687

Source DB:  PubMed          Journal:  Dermatology        ISSN： 1018-8665            Impact factor:   5.366


  6 in total

Review 1.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 2.  Managing the adverse effects of interferon-beta therapy in multiple sclerosis.

Authors:  A Bayas; P Rieckmann
Journal:  Drug Saf       Date:  2000-02       Impact factor: 5.606

Review 3.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

4.  Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.

Authors:  Annette Kolb-Mäurer; Matthias Goebeler; Mathias Mäurer
Journal:  Int J Mol Sci       Date:  2015-07-02       Impact factor: 5.923

5.  Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.

Authors:  Gita Faghihi; Akram Basiri; Mohsen Pourazizi; Bahareh Abtahi-Naeini; Ali Saffaei
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun

6.  Interferon-gamma-induced local leukocytoclastic vasculitis at the subcutaneous injection site.

Authors:  Fang Wang; Juan-Hua Liu; Yu-Kun Zhao; Di-Qing Luo
Journal:  An Bras Dermatol       Date:  2016 Sep-Oct       Impact factor: 1.896
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.